Needham lowers Vertex stock price target to $30 on slower growth
NegativeFinancial Markets

Needham has lowered its price target for Vertex Pharmaceuticals' stock to $30, citing concerns over slower growth. This adjustment reflects a cautious outlook on the company's future performance, which could impact investor confidence and market dynamics. As Vertex navigates these challenges, stakeholders will be closely watching how the company adapts to maintain its competitive edge.
— Curated by the World Pulse Now AI Editorial System









